A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
Advanced Solid Tumor
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 316 (final count)
- Started
- Nov 20, 2019
- Main results expected
- Dec 4, 2023
- Fully finished
- Feb 28, 2026
- Results posted
- Feb 24, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Broad Panel and Pediatric Cohorts: Objective Response Rate (ORR) Based on Response Assessment in Neuro-Oncology (RANO) as Assessed by Independent Review Committee (IRC)
Measured over: Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 4 years
Core Panel Cohort: Objective Response Rate (ORR) Based on Response Assessment in Neuro-Oncology (RANO) as Assessed by Independent Review Committee (IRC)
Measured over: Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 4 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04083976 · record last updated 2026-09-17 · checked 2026-11-09 15:47 UTC